SAB Biotherapeutics, Inc. (SABS)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about SAB Biotherapeutics, Inc. (SABS)
Company Performance

Current Price

as of Oct 18, 2024

$3.01

P/E Ratio

N/A

Market Cap

$27.78M

Description

SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. It is engaged in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. SAB Biotherapeutics was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.

Metrics

Overview

  • HQMiami Beach, FL
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerSABS
  • Price$3.01+9.06%

Trading Information

  • Market Cap$27.78M
  • Float81.12%
  • Average Daily Volume (1m)112,336
  • Average Daily Volume (3m)47,008
  • EPS-$6.17

Company

  • Revenue$2.78M
  • Rev Growth (1yr)207.70%
  • Net Income-$7.34M
  • Gross Margin-288.39%
  • EBITDA Margin-3,488.56%
  • EBITDA-$9.18M
  • EV-$3.29M
  • EV/Revenue-1.18
  • P/EN/A
  • P/S10.02
  • P/B0.60
Documents
SEC Filings
8-K (2024-09-09)
8-K (2024-07-31)
8-K (2024-06-27)
8-K (2024-05-31)
8-K (2024-05-21)
8-K (2024-05-08)
8-K (2024-04-15)
8-K (2024-03-29)
8-K (2024-03-08)
8-K (2024-02-02)
8-K (2024-01-26)
8-K (2024-01-25)
8-K (2024-01-19)
8-K (2024-01-03)
8-K (2023-11-29)
8-K (2023-11-22)
8-K (2023-11-20)
8-K (2023-10-27)
8-K (2023-10-02)
8-K (2023-08-21)
8-K (2023-07-31)
8-K (2023-07-03)
8-K (2023-06-21)
8-K (2023-06-14)
8-K (2023-05-12)
8-K (2023-04-28)
8-K (2023-04-19)
8-K (2023-04-14)
8-K (2023-04-04)
8-K (2023-03-31)
8-K (2023-03-24)
8-K (2023-02-07)
8-K (2023-01-27)
8-K (2023-01-10)
8-K (2023-01-09)
8-K (2023-01-05)
10-Q (2024-08-08)
10-Q (2024-05-20)
10-Q (2023-11-13)
10-Q (2023-08-21)
10-Q (2023-05-15)
10-K (2024-03-29)
10-K (2023-04-14)
Factset
Factset Business Description
Factset Street Account
SAB Biotherapeutics reports Q3 EPS ($0.10) vs FactSet ($0.12) [3 est, ($0.13)-(0.10)] - 10-Q ($0.93, 0.00) (2023-11-13T22:24:55Z)
SAB Biotherapeutics downgraded to neutral from buy at Ladenburg Thalmann ($0.71, 0.00) (2023-10-05T11:40:51Z)
SAB Biotherapeutics announces private placement of ~$130M, through Chardan, to advance development of lead drug candidate for Type 1 Diabetes ($0.63, 0.00) (2023-10-02T11:46:31Z)
SAB Biotherapeutics announces Michael G. King named CFO ($0.97, 0.00) (2023-10-24T11:35:24Z)
SAB Biotherapeutics announces funding of second tranche of previously-announced financing, raising total aggregate proceeds to date of $67.1M ($0.93, 0.00) (2023-11-14T12:37:41Z)
SAB Biotherapeutics announces commencement of the HUMAN Phase 1 clinical trial with SAB-142, a potential disease-modifying treatment for Type 1 Diabetes ($0.92, 0.00) (2023-11-29T12:37:25Z)
Follow up: SAB Biotherapeutics reaffirms guidance ($0.93, 0.00) (2023-11-14T12:17:45Z)